CIK 0001651308
- Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 981209416
- Phone
- +41 616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- 4 Grant or award Director acquired 18,980 shares (grant or award)
- 4 Grant or award Director acquired 18,980 shares (grant or award)
- 4 Grant or award Director acquired 18,980 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 37,960 shares (grant or award)
- 4 Open-market sale Principal Accounting Officer sold 136 shares at an average $271.33 ($36,901)
- 4 Open-market sale SVP, General Counsel sold 871 shares at an average $270.42 ($235,539)
- 4 Open-market sale President, Global Head of R&D sold 1,367 shares at an average $269.38 ($368,247)
- 4 Open-market sale President and COO sold 1,484 shares at an average $269.37 ($399,738)
- 4 Open-market sale Chief Executive Officer sold 4,940 shares at an average $270.56 ($1,336,548)
- 4 Open-market sale Director sold 235 shares at $279.13 ($65,596)
- 4 Open-market sale Director sold 212 shares at $309.51 ($65,617)
- 4 Open-market sale Director sold 212 shares at $309.60 ($65,636)
- 4 Open-market sale Director sold 212 shares at $309.59 ($65,633)
- 4 Open-market sale Director sold 10,998 shares at an average $23.82 ($261,981)
- 3/A Insider 3/A
- 4 Planned sale SVP, General Counsel sold 332 shares at $310.72 ($103,159)
- 4 Planned sale SVP, General Counsel sold 332 shares at $311.59 ($103,448)
- 4 Planned sale SVP, General Counsel sold 341 shares at $300.00 ($102,300)
Page 3 of 29 · 580 filings